In November 2021, APS will attend the JPMorgan 2022 BIO Partnering Conference from January 10-14, 2022. Dr. Jun Zhong, Vice President of Research and Development, and Dr. John Zhu, Vice President of Clinical Translation and Business Development, will attend the conference to introduce the company‘s unique research and development platform and projects, including the next-generation RET inhibitors APS03118, FGFR2 inhibitors, FGFR2/3/4 inhibitors and CDK7 inhibitors. We welcome teams with clinical and commercial transformation advantages to communicate with us at the conference. We are looking for international commercialization rights transfer or cooperative development of the project, and we are also looking for the introduction of early clinical innovation projects.